Main menu
Common skin conditions
NEWS
Join DermNet PRO
Read more
Quick links
" data-index="1" alt="Go to Introduction
" onclick="event.preventDefault();document.getElementsByTagName('h2')[(1 - 1)].scrollIntoView({behavior: 'smooth',block: 'start'});">Introduction
" data-index="2" alt="Go to General measures
" onclick="event.preventDefault();document.getElementsByTagName('h2')[(2 - 1)].scrollIntoView({behavior: 'smooth',block: 'start'});">General measures
" data-index="3" alt="Go to Reinfection reduction
" onclick="event.preventDefault();document.getElementsByTagName('h2')[(3 - 1)].scrollIntoView({behavior: 'smooth',block: 'start'});">Reinfection reduction
Antifungal drug resistance
Treatment of fungal infection may include:
Fungal spores can survive long periods. The following measures can be used to reduce the chance of reinfection.
In recent years, both topical and oral allylamine and triazole antifungal drug resistance has become a problem, particularly in the Indian subcontinent.
Extensive therapy-resistant dermatophyte infection should prompt this as a possible problem. Where available, fungal culture and estimation of drug minimum inhibitory concentration determined to guide appropriate medication
For more information, see antifungal drug resistance
Approved datasheets are the official source of information for medicines, including approved uses, doses, and safety information. Check the individual datasheet in your country for information about medicines.
We suggest you refer to your national drug approval agency such as the Australian Therapeutic Goods Administration (TGA), US Food and Drug Administration (FDA), UK Medicines and Healthcare products regulatory agency (MHRA) / emc, and NZ Medsafe, or a national or state-approved formulary eg, the New Zealand Formulary (NZF) and New Zealand Formulary for Children (NZFC) and the British National Formulary (BNF) and British National Formulary for Children (BNFC).